Table 1 Characteristics of randomized controlled trials included in the review
Study | Setting | Participants (n) | Groups (n) | Male, n (%) | Frequency of RHL (mean episodes/year) |
|---|---|---|---|---|---|
Hull et al. 2010 [18] | 51 sites in the United States and 4 sites in Canada (July 2006 to December 2007) | 1443 | Intervention | 406 (28) | 5.6 |
1. ME-609 cream (5% Acyclovir, 1% Hydrocortisone) (n = 601) | |||||
Control | |||||
1. Acyclovir (5% in ME-609 vehicle) (n = 610) | |||||
2. Placebo (vehicle) (n = 232) | |||||
Evans et al. 2002 [19] | 4 major university clinics in North America | 380 | Intervention | 76 (20) | 5.3 |
1. ME-609 cream (5% Acyclovir, 1% Hydrocortisone) (n = 190) | |||||
Control | |||||
1. Placebo (n = 190) | |||||
Hull et al. 2009 [20] | University of Utah (August 2004 to March 2007) | 39 | Intervention | 13 (33) | 4.5 |
1. Oral Valacyclovir (2 g 2×/day for 1 day) plus topical Clobetasol gel (0.05% 2×/day for 3 days) (n = 20) | |||||
Control | |||||
1. Placebo (n = 19) | |||||
Spruance et al. 2000 [21] | University of Utah Health Sciences Center, Salt Lake City | 29 | Intervention | 14 (29) | 5 |
1. Oral Famciclovir (Famvir, 500 mg 3×/day for 5 days) plus topical Fluocinonide (0.05% Lidex Gel 3×/day for 5 days) (n = 17) | |||||
Control | |||||
1. Famciclovir and topical vehicle control (n = 12) |